Interim analysis of a phase I/II study of panobinostat in combination with bevacizumab for recurrent glioblastoma.
Eudocia Quant Lee
Consultant or Advisory Role - Genentech; Novartis
Honoraria - American Academy of Neurology; Demos Medical Publishing; Springer Publishing; UpToDate
David A. Reardon
Consultant or Advisory Role - Amgen; EMD Serono; Genentech/Roche; Merck; Novartis
Honoraria - EMD Serono; Genentech/Roche; Merck
David Schiff
Consultant or Advisory Role - Genentech
Jan Drappatz
No relevant relationships to disclose
Alona Muzikansky
No relevant relationships to disclose
Samantha Hammond
No relevant relationships to disclose
Sean Aaron Grimm
Consultant or Advisory Role - Genentech
Andrew David Norden
No relevant relationships to disclose
Rameen Beroukhim
Consultant or Advisory Role - Novartis
Stock Ownership - AstraZeneca
Honoraria - Novartis
Research Funding - Novartis
Christine Sceppa McCluskey
No relevant relationships to disclose
Andrew S. Chi
No relevant relationships to disclose
Tracy Batchelor
Consultant or Advisory Role - Advanced Medical; Champions Biotechnology; Kyowa Hakko Kirin; Merck; Roche; Spectrum Pharmaceuticals
Honoraria - American Society of Hematology; Educational Concepts Group; Oakstone Medical Publishing; Research to Practice; Robert Michael Educational Institute; UpToDate
Research Funding - AstraZeneca; Millennium; Pfizer
Katrina H. Smith
No relevant relationships to disclose
Sarah C. Gaffey
No relevant relationships to disclose
Mary Gerard
No relevant relationships to disclose
Susan M. Snodgrass
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey J. Raizer
Consultant or Advisory Role - Genentech; Novartis
Honoraria - Merck; Roche/Genentech
Research Funding - Genentech; Novartis
Patrick Y. Wen
Consultant or Advisory Role - Novartis
Honoraria - Genentech; Novartis
Research Funding - Genentech; Novartis